BIOA
NASDAQ HealthcareBioAge Labs, Inc. - Common Stock
Drug Manufacturers - Specialty & Generic
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
�� 市场数据
| 价格 | $18.49 |
|---|---|
| 成交量 | 483,648 |
| 市值 | 820.58M |
| RSI（14日） | 66.4 |
| 200日均线 | $11.23 |
| 50日均线 | $19.21 |
| 52周最高 | $24.00 |
| 52周最低 | $3.67 |
| Forward P/E | -6.66 |
| Price / Book | 2.54 |
🎯 投资策略评分
BIOA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (35/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (8/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 BIOA in your text
粘贴任何文章、记录或帖子 — 工具将提取 BIOA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.